$1.00
Add to Cart
Circulating Tumor DNA Sequencing
More than 10 available
Details
Shipping: US-Mainland: free (more destinations)
Condition: Brand new
*The store has not been updated recently. You may want to contact the merchant to confirm the availability of the product.
"CD Genomics provides accurate Circulating Tumor DNA Sequencing services using next-generation sequencing (NGS) technology.
Cell-free, circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies. Today, researchers are investigating the use of ctDNA as a biomarker for detecting the presence of tumors in various cancer types. In the future, ctDNA could potentially serve as a noninvasive approach for real-time monitoring of treatment response and identifying candidates for therapy.
Next-generation sequencing (NGS) offers the sensitivity and specificity needed to detect low levels of ctDNA in the bloodstream. In addition to targeting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA. More information, please visit the website: http://www.cd-genomics.com/Circulating-Tumor-DNA-Sequencing.html"
Cell-free, circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies. Today, researchers are investigating the use of ctDNA as a biomarker for detecting the presence of tumors in various cancer types. In the future, ctDNA could potentially serve as a noninvasive approach for real-time monitoring of treatment response and identifying candidates for therapy.
Next-generation sequencing (NGS) offers the sensitivity and specificity needed to detect low levels of ctDNA in the bloodstream. In addition to targeting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA. More information, please visit the website: http://www.cd-genomics.com/Circulating-Tumor-DNA-Sequencing.html"
